綠盟科技(300369.SZ):2019年淨利預增24.95%-42.80%
格隆匯1月20日丨綠盟科技(300369.SZ)披露2019年度業績預告,公司預計2019年1-12月歸屬於上市公司股東的淨利潤為2.1億元~2.4億元,同比增長24.95%~42.80%。業績變動原因如下:
1.報告期內公司經營和財務狀況良好,歸屬於上市公司股東的淨利潤同比預計增長24.95%-42.80%;報告期內公司加大產品及解決方案的研發投入,加強貼近客户的組織建設、與生態合作伙伴的體系建設,公司保持良性發展。
2.預計2019年度非經常性損益對歸屬於上市公司股東的淨利潤影響額約為4857.00萬元,2018年度非經常性損益對淨利潤的影響金額為4581.97萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.